rct
    2022
    High Quality

    N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: a phase III, 20-week, double-blind, randomized, placebo-controlled trial

    Sarris J, Byrne G, Castle D

    Published in Progress in Neuro-Psychopharmacology and Biological Psychiatry

    Key Findings

    In 98 adults with OCD, NAC 2-4 g/day showed no benefit over placebo on Y-BOCS or secondary outcomes.

    Conclusions

    No evidence supporting the efficacy of adjunctive NAC in OCD.

    Supplements Studied

    A modified intention-to-treat analysis of the primary outcome found no evidence that NAC reduced symptoms of OCD measured on the Yale-Brown Obsessive-Compulsive Scale, relative to placebo.

    Related Health Concerns

    Intrusive Thoughts
    Obsessive-Compulsive Disorder

    Study Details

    Year:2022
    Quality Score:8/10

    Access Study

    View on DOIView on PubMedOriginal Source

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.